Clinical trial
sPLA2 Inhibition to Decrease Enzyme Release After PCI (SPIDER-PCI) Trial
NCT00533039 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- sPLA2 Inhibition to Decrease Enzyme Release After PCI (SPIDER-PCI) Trial
- Lead sponsor
- University Health Network, Toronto
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 31, 2007
- Completion date
- June 30, 2009
- Enrollment
- 164 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.